

D O'Riordpharm Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 December 2025

D O'Riordpharm Limited
CONTENTS

	Page
Directors' Responsibilities Statement	3
Statement of Financial Position	4
Notes to the Financial Statements	5 - 10

D O'Riordpharm Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2025

The directors made the following statement in respect of the unaudited financial statements:

"General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Statement of Financial Position and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to Fitzpatrick Donnellan Limited, (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 December 2025."

Signed on behalf of the board

Diarmuid O'Riordan
Director

27 February 2026

Aine O'Riordan
Director

27 February 2026

D O'Riordpharm Limited
STATEMENT OF FINANCIAL POSITION

as at 31 December 2025

	Notes	2025 €	2024 €
Non-Current Assets			
Intangible assets	5	194,721	263,446
Property, plant and equipment	6	41,374	29,403
Financial assets	7	100	100
Non-Current Assets		236,195	292,949
Current Assets			
Stocks	8	114,025	113,568
Debtors	9	179,316	172,254
Cash and cash equivalents		256,346	377,788
		549,687	663,610
Creditors: amounts falling due within one year	10	(157,694)	(148,574)
Net Current Assets		391,993	515,036
Total Assets less Current Liabilities		628,188	807,985
Capital and Reserves			
Called up share capital presented as equity		100	100
Retained earnings	11	628,088	807,885
Equity attributable to owners of the company		628,188	807,985

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of D O'Riordpharm Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 27 February 2026 and signed on its behalf by:

Diarmuid O'Riordan
Director

Aine O'Riordan
Director

D O'Riordpharm Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

1. General Information

D O'Riordpharm Limited is a company limited by shares incorporated in Ireland. Main Street, Athea, Co.Limerick, Ireland is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280B of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Consolidated accounts

The company is entitled to the exemption provided for in section 293 (1A) of the Companies Act 2014 from the obligation to prepare group accounts because it qualifies as a small company in accordance with the small companies' regime.

Turnover

Turnover represents the total invoice value, excluding value added tax, of sales made during the year.

Goodwill

Purchased goodwill arising on the acquisition of a business represents the excess of the acquisition cost over the fair value of the identifiable net assets including other intangible fixed assets when they were acquired. Purchased goodwill is capitalised in the Statement of Financial Position and amortised on a straight line basis over its economic useful life of 20 years, which is estimated to be the period during which benefits are expected to arise. On disposal of a business any goodwill not yet amortised is included in determining the profit or loss on sale of the business.

Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Fit out costs	-	12.5% Straight Line
Fixtures, fittings and equipment	-	12.5% Straight Line
Motor vehicles	-	12.5% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment if events or changes in circumstances indicate the carrying value may not be recoverable.

Financial assets

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Income Statement in the year in which it is receivable.

D O'Riordpharm Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 December 2025

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Statement of Financial Position bank overdrafts are shown within Creditors.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Income Statement annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Income Statement when received.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging/(crediting):		
Depreciation of property, plant and equipment	9,096	8,136
Amortisation of goodwill	68,725	68,725
Government grants received	(444)	(5,645)
	<u> </u>	<u> </u>

D O'Riordpharm Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 December 2025

4. Employees

The average monthly number of employees, including directors, during the financial year was 13, (2024 - 13).

	2025	2024
	Number	Number
Employees	<u>13</u>	<u>13</u>

5. Intangible assets

	Goodwill	Total
	€	€
Cost		
At 1 January 2025	<u>1,374,500</u>	<u>1,374,500</u>
At 31 December 2025	<u>1,374,500</u>	<u>1,374,500</u>
Provision for diminution in value		
At 1 January 2025	1,111,054	1,111,054
Charge for financial year	<u>68,725</u>	<u>68,725</u>
At 31 December 2025	<u>1,179,779</u>	<u>1,179,779</u>
Net book value		
At 31 December 2025	<u>194,721</u>	<u>194,721</u>
At 31 December 2024	<u>263,446</u>	<u>263,446</u>

6. Property, plant and equipment

	Fit out costs	Fixtures, fittings and equipment	Motor vehicles	Total
	€	€	€	€
Cost				
At 1 January 2025	154,568	15,910	35,404	205,882
Additions	560	20,507	-	21,067
Disposals	<u>(6,190)</u>	<u>(1,099)</u>	<u>-</u>	<u>(7,289)</u>
At 31 December 2025	<u>148,938</u>	<u>35,318</u>	<u>35,404</u>	<u>219,660</u>
Depreciation				
At 1 January 2025	133,497	14,955	28,027	176,479
Charge for the financial year	3,022	1,649	4,425	9,096
On disposals	<u>(6,190)</u>	<u>(1,099)</u>	<u>-</u>	<u>(7,289)</u>
At 31 December 2025	<u>130,329</u>	<u>15,505</u>	<u>32,452</u>	<u>178,286</u>
Net book value				
At 31 December 2025	<u>18,609</u>	<u>19,813</u>	<u>2,952</u>	<u>41,374</u>
At 31 December 2024	<u>21,071</u>	<u>955</u>	<u>7,377</u>	<u>29,403</u>

D O'Riordpharm Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 December 2025

7. Financial fixed assets

	Subsidiary undertakings shares	Total
	€	€
Investments		
Cost		
At 31 December 2025	100	100
Net book value		
At 31 December 2025	<u>100</u>	<u>100</u>
At 31 December 2024	<u>100</u>	<u>100</u>

7.1. Holdings in related undertakings

The company holds 20% or more of the share capital of the following company:

Name	Registered office / Principal place of business and address of Registered Office	Nature of business	Details of investment	Proportion held by company
Subsidiary undertaking				
Adcaspharm Limited	Ireland	Pharmacy	Ordinary	100%

The aggregate amount of capital and reserves and the results of these undertakings for the last relevant financial year were as follows:

	Year ended	Capital and reserves €	Profit for the year €
Adcaspharm Limited	31 December 2022	<u>100</u>	<u>-</u>

In the opinion of the directors, the shares of the company's unlisted investments are worth at least the amount at which they are stated in the Statement of Financial Position.

8. Stocks	2025	2024
	€	€
Finished goods and goods for resale	<u>114,025</u>	<u>113,568</u>
9. Debtors	2025	2024
	€	€
Trade debtors	92,226	86,059
Taxation	77,659	82,074
Prepayments	9,431	4,121
	<u>179,316</u>	<u>172,254</u>

D O'Riordpharm Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

10. Creditors	2025	2024
Amounts falling due within one year	€	€
Trade creditors	89,077	79,127
Taxation	40,149	42,512
Directors' current accounts (Note 13)	13,918	13,024
Accruals	14,550	13,911
	<u>157,694</u>	<u>148,574</u>

11. Income Statement	2025	2024
	€	€
At 1 January 2025	807,885	927,889
Profit for the financial year	170,203	179,996
Payment of dividends	(350,000)	(300,000)
	<u>628,088</u>	<u>807,885</u>
At 31 December 2025	<u>628,088</u>	<u>807,885</u>

12. Capital commitments

The company had no material capital commitments at the 31 December 2025.

13. Directors' remuneration and transactions	2025	2024
	€	€
Remuneration	48,225	39,999
Pension contributions	13,160	12,433
	<u>61,385</u>	<u>52,432</u>

The following amounts are repayable to the directors:

	2025	2024
	€	€
Diarmuid O'Riordan	<u>13,918</u>	<u>13,024</u>

14. Related party transactions

The business premises are rented to the company by the directors, Diarmuid and Aine O'Riordan, at an annual rent of €36,900. During the year ended 31st December 2024, the directors were paid rent of €36,900 by D O'Riordpharm Limited.

Adcaspharm Limited

D O'Riordpharm Limited owns 100% of the share capital of Adcaspharm Limited which was incorporated on 27th May 2016.

The companies are related by virtue of Diarmuid O'Riordan being a common director.

Adcalads Limited incorporated on 4th September 2023 owns 100% of the share capital of D O'Riordpharm Limited.

The business premises are rented to the company by the directors, Diarmuid and Aine O'Riordan, at an annual rent of €36,900. During the year ended 31st December 2024, the directors were paid rent of €36,900 by D O'Riordpharm Limited.

D O'Riordpharm Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 December 2025

15. Parent and ultimate parent company

The company regards Adcalads Limited as its parent company.

The company's ultimate parent undertaking is Adcalads Limited.

16. Events After the End of the Reporting Period

There have been no significant events affecting the company since the financial year-end.

17. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 27 February 2026.